{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Artivion, Inc. Hits New 52-Week High of $47.69, Up 104%
Artivion, Inc. has achieved a new 52-week high of USD 47.69, reflecting a significant increase in its stock price over the past year. With a market capitalization of USD 2,114 million, the company operates in a competitive sector, though it currently reports a negative return on equity.
Artivion, Inc. Hits New 52-Week High of $46.58, Up 96.65%
Artivion, Inc. has achieved a new 52-week high, highlighting its impressive performance with a significant increase over the past year. The company, with a market capitalization of USD 2,114 million, operates in a competitive sector and currently shows a manageable debt level, despite being loss-making.
Artivion, Inc. Hits New 52-Week High of $46.19, Up 96% Yearly
Artivion, Inc. has achieved a new 52-week high, showcasing a significant increase from its previous low and demonstrating strong performance compared to the S&P 500. With a market capitalization of USD 2,114 million, the company operates in a competitive sector, though it remains loss-making and does not offer dividends.
Is Artivion, Inc. technically bullish or bearish?
As of September 5, 2025, Artivion, Inc. shows a mildly bullish trend with positive momentum from MACD and Bollinger Bands, but mixed signals from RSI and recent negative returns suggest caution.
Is Artivion, Inc. overvalued or undervalued?
As of February 17, 2022, Artivion, Inc. has shifted from an attractive to a risky valuation due to overvaluation indicators like a Price to Book Value of 4.35 and an EV to EBITDA ratio of 32.14, coupled with low ROCE of 4.31% and negative ROE of -4.00%, despite a strong year-to-date return of 44.67%.
Is Artivion, Inc. technically bullish or bearish?
As of June 17, 2025, Artivion, Inc. shows a neutral trend with mixed signals, as weekly indicators are bullish while daily moving averages are mildly bearish, resulting in a weak overall trend with no clear direction.
Is Artivion, Inc. overvalued or undervalued?
As of February 17, 2022, Artivion, Inc. is considered overvalued and risky due to high financial ratios and negative earnings metrics, despite a recent 32.23% stock return.
Who are in the management team of Artivion, Inc.?
As of March 2022, the management team of Artivion, Inc. includes Chairman and CEO James Mackin, Presiding Independent Director Ronald McCall, and independent directors Thomas Ackerman, Daniel Bevevino, Marna Borgstrom, and James Bullock. This team provides governance and strategic direction for the company.
What does Artivion, Inc. do?
Artivion, Inc. is a medical device manufacturer specializing in implantable human tissues for cardiac surgeries, classified as a Micro Cap company with a market cap of approximately $1.32 billion. As of March 2025, it reported net sales of $99 million and a net profit of -$1 million.
How big is Artivion, Inc.?
As of Jun 18, Artivion, Inc. has a market capitalization of 1,315.53 million, classifying it as a Micro Cap company, with net sales of 390.09 million and a net profit of -21.36 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
